drugset / Trial / NCT00574236
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Phase 2
Terminated
4 enrolled
University of Wisconsin, Madison
Millennium Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
Primary objective is to determine the effectiveness of the combination of bortezomib and doxorubicin in patients with metastatic breast cancer. The trial format is a single arm Phase II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and with doxorubicin IV on days 1 and 8 of a 21-day cycle.
Timeline
- Start
- 2006-08
- Primary completion
- 2009-10
- Completion
- 2009-10
Outcome
Outcome not reported
Stopped (Business): “no additional funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |